---
title: "IDEXX Laboratories Inc. Stock Underperforms Tuesday When Compared To Competitors"
description: "IDEXX Laboratories Inc. (IDXX) shares fell 1.10% to $632.56 on Tuesday, marking the sixth consecutive day of losses. The stock is now 17.85% below its 52-week high of $769.98. In contrast, competitors"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274718219.md"
published_at: "2026-02-03T21:50:52.000Z"
---

# IDEXX Laboratories Inc. Stock Underperforms Tuesday When Compared To Competitors

> IDEXX Laboratories Inc. (IDXX) shares fell 1.10% to $632.56 on Tuesday, marking the sixth consecutive day of losses. The stock is now 17.85% below its 52-week high of $769.98. In contrast, competitors like Johnson & Johnson (JNJ) and Medtronic PLC (MDT) saw gains of 1.02% and 0.46%, respectively. The overall market also declined, with the S&P 500 down 0.84%. Trading volume for IDXX was 632,848, surpassing its 50-day average of 547,981.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of IDEXX Laboratories Inc. (IDXX) slipped 1.10% to $632.56 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.84% to 6,917.81 and Dow Jones Industrial Average falling 0.34% to 49,240.99.

This was the stock's sixth consecutive day of losses.

IDEXX Laboratories Inc. closed 17.85% below its 52-week high of $769.98, which the company reached on November 26th.

The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 1.02% to $233.10, Medtronic PLC (MDT) rose 0.46% to $103.18, and Boston Scientific Corp. (BSX) fell 0.27% to $91.62.

Trading volume (632,848) eclipsed its 50-day average volume of 547,981.

Data source: Dow Jones Market Data, FactSet. Data compiled February 3, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-03-26 1650ET

### Related Stocks

- [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md)
- [IDXX.US - IDEXX Labs](https://longbridge.com/en/quote/IDXX.US.md)
- [IDNA.US - iShares Genomics Immunology and Healthcare ETF](https://longbridge.com/en/quote/IDNA.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 就业数据强劲打击降息预期，美股基金遭遇三周以来首次资金净流出 | 强劲就业数据削弱降息预期，叠加 AI 颠覆担忧，导致美股基金遭遇三周来首次资金净流出（14.2 亿美元）。资金显著分化：大盘股失血 123.4 亿美元，小盘股逆势吸金 20.1 亿美元。避险下债券基金连续六周获流入，货币基金遭赎回。 | [Link](https://longbridge.com/en/news/275904573.md) |
| BUZZ-Immunic 股价大涨，因该生物技术公司筹集最多达 4 亿美元用于多发性硬化症药物试验 | Immunic 的股票在盘前交易中上涨了 32%，达到 1.15 美元，因为这家生物技术公司宣布将为其多发性硬化症药物 vidofludimus calcium 的后期试验筹集高达 4 亿美元的资金。此次融资包括 2 亿美元的预付款和 2  | [Link](https://longbridge.com/en/news/275896435.md) |
| 投资者警报：Pomerantz 律师事务所代表 Vanda 制药公司（股票代码：VNDA）的投资者进行索赔调查 | Pomerantz 律师事务所正在代表 Vanda Pharmaceuticals Inc.（纳斯达克代码：VNDA）的投资者调查有关该公司及其高管可能存在的证券欺诈或非法商业行为的索赔。这一调查是基于 Vanda 发布的新闻稿，该稿称 F | [Link](https://longbridge.com/en/news/275824878.md) |
| Ultragenyx 在重组期间第四季度收入增长了 25% | Ultragenyx 报告称，2025 年第四季度收入增长了 25%，主要得益于 Crysvita 和 Evkeeza 的强劲销售。该公司正在进行战略重组，裁减 10% 的员工，并预计 2026 年收入将增长 8% 至 13%，目标为 7. | [Link](https://longbridge.com/en/news/275807559.md) |
| Soligenix 为股东提供关于罕见病研发管线的最新更新 | Soligenix（SNGX）于 2026 年 2 月 12 日发布了股东更新，详细介绍了其罕见疾病管线的进展，包括针对皮肤 T 细胞淋巴瘤的第三阶段 FLASH2 试验，目前已招募 66 名患者，目标为 80 名。公司报告了 SGX945 | [Link](https://longbridge.com/en/news/275812846.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
